Stem cells and cancer;Células madre y cáncer

Investigacion Clinica (Venezuela)

Volumn 55, Issue 4, 2014, Pages 371-391

  Arvelo, Francisco ^a,b   Cotte, Carlos ^b   Sojo, Felipe ^a,b  

^a Fundacion Instituto de Estudios Avanzados IDEA   (Venezuela)

^b FACULTAD DE CIENCIAS   (Venezuela)

Author keywords

Cancer; Carcinogenesis; Chemotherapy; Differentiation; Dormancy; Metastasis; Signaling pathway; Tumor stem cell

Indexed keywords

ARTICLE; CANCER RESEARCH; CANCER STEM CELL; DORMANCY; DRUG RESISTANCE; HUMAN; HUMAN CELL; METASTASIS; SIGNAL TRANSDUCTION; TUMOR RECURRENCE; ANIMAL; BIOLOGICAL MODEL; CELL DIFFERENTIATION; CELL TRANSFORMATION; CLASSIFICATION; CYTOLOGY; DRUG EFFECTS; MOUSE; NEOPLASMS; PATHOLOGY; PHYSIOLOGY; RADIATION RESPONSE; STEM CELL; TUMOR EMBOLISM;

SIGNAL PEPTIDE; TUMOR PROTEIN;

ANIMALS; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 84925222288     PISSN: 05355133     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (146)

1. Arvelo F, Poupon MF. Aspectos moleculares y celulares de la metástasis cancerosa. Acta Cient Venez 2001; 52: 304-312.
2. Li Y, Laterra J. Cancer stem cells: Distinct entities or dynamically regulated phenotypes? Cancer Res 2012; 72: 576- 580.
3. Weinberg RA. The molecular basis of oncogenes and tumor suppressor genes. Ann N Y Acad Sci 1995; 758: 331-338.
4. Bosch-Barrera J, Lopez-Picazo Gonzalez JM, Garcia-Foncillas Lopez J, Prosper Cardoso F. Células madre y cáncer: dilucidando el origen de la célula madre tumoral. Rev Med Univ Navarra 2007; 51: 14-17.
5. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med 2006; 12: 296-300.
6. Zhang M, Rosen JM. Stem cells in the etiology and treatment of cancer. Curr Opin Genet Dev 2006; 16: 60-64.
7. Maitland NJ, Collins A. A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int 2005; 96: 1219-1223.
8. Dontu G, Al Hajj M, Abdallah WM, Clarke MF, Wicha MS. Stem cells in normal breast development and breast cancer. Cell Prolif 2003; 36 (Suppl 1): 59-72.
9. Maitra A, Arking DE, Shivapurkar N, Ikeda M, Stastny V, Kassauei K. Genomic alterations in cultured human embryonic stem cells. Nat Genet 2005; 37(10): 1099-1103.
10. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
11. Stem Cells. Scientific Progress and Future Research Directions. Report Prepared by the National Institute of the Health, USA, June 2001.
12. Arvelo F, Pérez P, Cotte C. Obtención de láminas de piel humana mediante ingeniería de tejidos. Acta Cient Venez 2004; 55: 74-82.
13. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 2010; 143: 508-525.
14. Langan RC, Mullinax JE, Raiji MT, Upham T, Summers T, Stojadinovic A, Avital I. Colorectal cancer biomarkers and the potential role of cancer stem cells. 2013; 4: 241-250.
15. Mackillop WJ, Ciampi A, Till JE, Buick RN. A stem cell model of human tumor growth: implications for tumor cell clonogenic assays. J Natl Cancer Inst 1983; 70:9-16.
16. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-737.
17. Blair A, Hogge DE, Ailles LE, Lansdorp PM, Sutherland HJ. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997; 89: 3104- 3112.
18. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 16; 104: 973-978.
19. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008; 15: 504-514.
20. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008; 13: 153-166.
21. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68: 4311-4320.
22. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106- 110.
23. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
24. Fredebohm J, Boettcher M, Eisen C, Gaida MM, Heller A, Keleg S, Tost J, Greulich-Bode KM, Hotz-Wagenblatt A, Lathrop M, Giese NA, Hoheisel JD. Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system. PLoS One 2012; 7: 1-14.
25. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-567.
26. Aomatsu N, Yashiro M, Kashiwagi S, Takashima T, Ishikawa T, Ohsawa M, Wakasa K, Hirakawa K. CD133 is a useful surrogate marker for predicting chemosensitivity to neoadjuvant chemotherapy in breast cancer. PLoS One. 2012; 7: 1-9.
27. Lugli A, Iezzi G, Hostettler I, Muraro MG, Mele V, Tornillo L, Carafa V, Spagnoli G, Terracciano L, Zlobec I. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010; 103: 382-390.
28. Rao QX, Yao TT, Zhang BZ, Lin RC, Chen ZL, Zhou H, Wang LJ, Lu HW, Chen Q, Di N, Lin ZQ. Expression and functional role of ALDH1 in cervical carcinoma cells. Asian Pac J Cancer Prev 2012; 13:1325- 1331.
29. Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang Y, Montone K, Bützow R, Coukos G, Zhang L. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One. 2010; 5: 1-11.
30. Guo W, Lasky J, Wu H. Cancer stem cells. Pediatr Res 2006; 59: 59R-64R.
31. Velasco M, De la Fuente Granada M. Papel de las células madres oncogénicas. Rev Venez Oncol 2009; 21: 174-182.
32. Yuan Y, Shen H, Franklin DS, Scadden DT, Cheng T. In vivo self-renewing divisions of haematopoietic stem cells are increased in the absence of the early G1-phase inhibitor, p18INK4C. Nat Cell Biol 2004; 6: 436-42.
33. Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts. Annu Rev Med 2007; 58: 267-284.
34. Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, Wicha MS. Cancer stem cells in breast: current opinion and future challenges. Pathobiology 2008; 75: 75-84.
35. Wong RS, Cheong SK. Leukaemic stem cells: drug resistance, metastasis and therapeutic implications. Malays J Pathol 2012; 34: 77-88.
36. Velasco-Velázquez MA, Homsi N, De La Fuente M, Pestell RG. Breast cancer stem cells. Int J Biochem Cell Biol 2012; 44: 573-577.
37. Ramakrishna R, Rostomily R. Seed, soil, and beyond: The basic biology of brain metastasis. Surg Neurol Int 2013; 4: S256-264.
38. Puglisi MA, Tesori V, Lattanzi W, Gasbarrini GB, Gasbarrini A. Colon cancer stem cells: Controversies and perspectives. World J Gastroenterol 2013; 19: 2997-3006.
39. Chinn SB, Darr OA, Peters RD, Prince ME. The role of head and neck squamous cell carcinoma cancer stem cells in tumorigenesis, metastasis, and treatment failure. Front Endocrinol (Lausanne) 2012; 3: 1-6.
40. Lee CJ, Dosch J, Simeone DM. Pancreatic cancer stem cells. J Clin Oncol 2008; 26: 2806-2812.
41. Hynes PG, Kelly K. Prostate cancer stem cells: The case for model systems. J Carcinog 2012; 11: 1-19.
42. Arvelo F, Morales A. Telómero, telomerasa y cáncer. Acta Cient Venez 2004; 55: 288-303.
43. Passegué E, Weisman IL. Leukemic stem cells: where do they come from? Stem Cell Rev 2005; 1: 181-188.
44. Passegué E, Jamieson CH, Ailles LE, Weissman IL. Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci USA 2003; 100 (Suppl 1):11842-11849.
45. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by definid factors. Cell 2006; 126: 663-676.
46. Yu J, Vodyanik M, Smuga-Otto K, Antosiewicz-Bouget J, Frane J, Tian S, Nie J, Jonsdottir G, Ruotti V, Stewart R. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
47. Kasimir-Bauer S, Hoffmann O, Wallwiener D, Kimmig R, Fehm T. Expression of stem cell and epithelialmesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 2012; 14: R15.
48. Akunuru S, James Zhai Q, Zheng Y. Non-small cell lung cancer stem/progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. Cell Death Dis 2012; 3:1-10.
49. Sipos F, Galamb O. Epithelial-tomesenchymal and mesenchymal-to-epithelial transitions in the colon. World J Gastroenterol 2012; 18: 601-608.
50. Iwasaki H, Suda T. Cancer stem cells and their niche. Cancer Sci 2009; 100: 1166-1172.
51. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res 2006; 66: 4553-4557.
52. Hsu YC, Fuchs E. A family business: stem cell progeny join the niche to regulate homeostasis. Nat Rev Mol Cell Biol 2012; 13: 103-114.
53. Inaba M, Yamashita YM. Asymmetric stem cell division: precision for robustness. Cell Stem Cell 2012; 11: 461-469.
54. Ozel C, Seidel J, Meyer-Staeckling S, Brandt BH, Niggemann B, Zänker KS, Dittmar T. Hybrid cells derived from breast epithelial cell/breast cancer cell fusion events show a differential RAF-AKT crosstalk. Cell Commun Signal 2012; 10:1-12.
55. Lu X, Kang Y. Cell fusion hypothesis of the cancer stem cell. Adv Exp Med Biol 2011; 714: 129-140.
56. Nagler C, Zänker KS, Dittmar T. Cell fusion, drug resistance and recurrence CSCs. Adv Exp Med Biol 2011; 714: 173-182.
57. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, Visvader J, Weissman IL, Wahl GM. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on Cancer Stem Cells. Cancer Res 2006; 39: 3-14.
58. Powell AE, Anderson EC, Davies PS, Silk AD, Pelz C, Impey S, Wong MH. Fusion between Intestinal epithelial cells and macrophages in a cancer context results in nuclear reprogramming. Cancer Res 2011; 71: 1497-1505.
59. Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 2012; 21: 283-296.
60. Thompson SL, Compton DA. Chromosomes and cancer cells. Chromosome Res 2011; 19: 433-444.
61. Mayora A, Arvelo F. Cáncer de próstata y apoptosis. Invest Clín 2011; 52: 376-396.
62. Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell 2007; 128: 635-638.
63. Moyret-Lalle C, Falette N, Grelier G, Puisieux A. Tumour genomics: an unstable landscape. Bull Cancer 2008; 95: 923-930.
64. Vilimas T, Mascarenhas J, Palomero T, Mandal M, Buonamici S, Meng F, Thompson B, Spaulding C, Macaroun S, Alegre ML, Kee BL, Ferrando A, Miele L, Aifantis I. Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med 2007; 13: 70-77.
65. Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 2013; 17: 30-54.
66. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003; 100:15178-15183.
67. Wu A, Oh S, Wiesner SM, Ericson K, Chen L, Hall WA, Champoux PE, Low WC, Ohlfest JR. Persistence of CD133+ cells in human and mouseglioma cell lines: detailed characterization of GL261 glioma cells withcancer stem cell-like properties. Stem Cells Dev 2008; 17: 173-184.
68. Hu YY, Zheng MH, Cheng G, Li L, Liang L, Gao F, Wei YN, Fu LA, Han H. Notch signaling contributes to the maintenance of both normal neural stem cells and patient- derived glioma stem cells. BMC Cancer 2011; 11:1-13.
69. Aguirre A, Rubio ME, Gallo V. Notch and EGFR pathway interaction regulates neural stem cell number and self-renewal. Nature 2010; 467: 323-327.
70. Yu Z, Pestell TG, Lisanti MP, Pestell RG. Cancer stem cells. Int J Biochem Cell Biol 2012; 44: 2144-2151.
71. Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der Heijden M, Moayedpardazi H, Correia AS, Soulet D, Major T, Menon J, Tabar V. Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 2010; 28: 1019-1029.
72. Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, Poser SW, Rueger MA, Bae SK, Kittappa R, McKay RD. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature 2006; 442: 823-826.
73. Huelsken J, Behrens J. The Wnt signalling pathway. J Cell Sci 2002; 115:3977- 3978.
74. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843- 850.
75. Polakis P. Drugging Wnt signalling in cancer. EMBO J 2012; 31:2737-2746.
76. Fre S, Pallavi SK, Huyghe M, Laé M, Janssen KP, Robine S, Artavanis- Tsakonas S, Louvard D. Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine. Proc Natl Acad Sci USA 2009; 106: 6309- 6314.
77. Shiras A, Chettiar ST, Shepal V, Rajendran G, Prasad GR, Shastry P. Spontaneous transformation of human adult nontumorigenic stem cells to cancer stem cells is driven by genomic instability in a human model of glioblastoma. Stem Cells 2007; 25: 1478-1489.
78. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149: 274-293.
79. Iglesias-Bartolome R, Gutkind JS. Signaling circuitries controlling stem cell fate: to be or not to be. Curr Opin Cell Biol 2011; 23:716-723.
80. Akcakanat A, Zhang L, Tsavachidis S, Meric-Bernstam F. The rapamycin-regulated gene expression signature determines prognosis for breast cancer. Mol Cancer 2009; 8:1-11.
81. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova- Todorova K, Holland EC. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 2008; 22: 436-448.
82. Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL, Kockel L. With TOR, less is more: a key role for the conserved nutrient-sensing TOR pathway in aging. Cell Metab 2010;11: 453-65.
83. Chong ZZ, Shang YC, Wang S, Maiese K. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol 2012; 99: 128-148.
84. Maiese K, Chong ZZ, Shang YC, Wang S. mTOR: on target for novel therapeutic strategies in the nervous system. Trends Mol Med 2013; 19:51-60.
85. Russell RC, Fang C, Guan KL. An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development 2011; 138: 3343-3356.
86. Qiu B, Zhang D, Tao J, Wu A, Wang Y. A simplified and modified procedure to culture brain glioma stem cells from clinical specimens. Oncol Lett 2012; 3: 50-54.
87. Song Z, Yue W, Wei B, Wang N, Li T, Guan L, Shi S, Zeng Q, Pei X, Chen L. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One 2011; 6: 1-13.
88. Rubio D, Garcia-Castro J, Martín MC, de la Fuente R, Cigudosa JC, Lloyd AC, Bernad A. Spontaneous human adult stem cell transformation. Cancer Res 2005; 65: 3035-3039.
89. Wu SM, Choo AB, Yap MG, Chan KK. Role of sonic hedgehog signaling and the expression of its components in human embryonic stem cells. Stem Cell Res 2010; 4: 38-49.
90. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz I Altaba A. HEDGEHOG- GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007; 17: 165-172.
91. Adolphe C, Hetherington R, Ellis T, Wainwright B. Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res 2006; 66: 2081-2088.
92. Basset-Seguin N, Soufir N. Voie Patched/Sonic Hedgehog et carcinomes basocellulaires. Med Sci (Paris) 2004; 20: 899-903.
93. Eccles SA. The epidermal growth factor receptor/ Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 2011; 55: 685-696.
94. Bao S, Wu Q, Li Z, Sathornsumetee S, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res 2008; 68: 6043-6048.
95. Held-Feindt J, Schmelz S, Hattermann K, Mentlein R, Mehdorn HM, Sebens S. The neural adhesion molecule L1CAM confers chemoresistance in human glioblastomas. Neurochem Int 2012; 61:1183-1191.
96. Cao Y, Lathia JD, Eyler CE, Wu Q, Li Z, Wang H, McLendon RE, Hjelmeland AB, Rich JN. Erythropoietin receptor signaling through STAT3 is required for glioma stem cell maintenance. Genes Cancer 2010; 1: 50-61.
97. Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112: 4793-4807.
98. Luo W, Yao K. Molecular characterization and clinical implications of spindle cells in nasopharyngeal carcinoma: a novel molecule- morphology model of tumor progression proposed. PLoS One 2013; 8: 1-12.
99. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N. Multipotentcell lineages in early mouse development depend on SOX2 function. Genes Dev 2003; 17: 126-140.
100. Pesce M, Schöler HR. Oct-4 gatekeeper in the beginnings of mammalian development. Stem Cells 2001; 19:271-278.
101. Mitsui K, Tokuzawa Y, Itoh H, Segawa K, Murakami M. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell 2003; 113: 631-642.
102. Arvelo F, Merentes E, Cotte C. Resistencia multidroga (MDR) o pleiotropica. Acta Cient Venez 2000; 51: 45-52.
103. Liu H, Patel MR, Prescher JA, Patsialou A, Qian D, Lin J, Wen S, Chang YF, Bachmann MH, Shimono Y, Dalerba P, Adorno M, Lobo N, Bueno J, Dirbas FM, Goswami S, Somlo G, Condeelis J, Contag CH, Gambhir SS, Clarke MF. Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci USA 2010; 107: 18115-18120.
104. Krantz SB, Shields MA, Dangi-Garimella S, Munshi HG, Bentrem DJ. Contribution of epithelial-to-mesenchymal transition and cancer stem cells to pancreatic cancer progression. J Surg Res 2012; 173: 105- 112.
105. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
106. Louie E, Nik S, Chen JS, Schmidt M, Song B, Pacson C, Chen XF, Park S, Ju J, Chen EI. Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res 2010; 12: R94.
107. Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 2013; 17: 30-54.
108. Rodríguez-Jiménez FJ, Moreno-Manzano V, Lucas-Dominguez R, Sánchez-Puelles JM. Hypoxia causes downregulation of mismatch repair system and genomic instability in stem cells. Stem Cells 2008; 26: 2052-2062.
109. Shinin V, Gayraud-Morel B, Gomès D, Tajbakhsh S. Asymmetric division and cosegregation of template DNA strands in adult muscle satellite cells. Nat Cell Biol 2006; 8: 677-687.
110. Fukunaga-Kalabis M, Herlyn M. Beyond ABC: another mechanism of drug resistance in melanoma side population. J Invest Dermatol 2012; 132: 2317-2319.
111. Luo Y, Ellis LZ, Dallaglio K, Takeda M, Robinson WA, Robinson SE, Liu W, Lewis KD, McCarter MD, Gonzalez R, Norris DA, Roop DR, Spritz RA, Ahn NG, Fujita M. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol 2012; 132: 2440-2450.
112. Natarajan K, Xie Y, Baer MR, Ross DD. Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance. Biochem Pharmacol 2012; 83: 1084-1103.
113. Wulf G, Wanq R, Kuehnle L, Weidner D, Marini F, Brenner M, Andref F, Goodell M. Leukemic stem cell with intrinsic efflux capacity in acute myeloid leukemia. Blood 2001; 98: 1166-1173.
114. Zhang F, Throm SL, Murley LL, Miller LA, Steven Zatechka D Jr, Kiplin Guy R, Kennedy R, Stewart CF. MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochem Pharmacol 2011; 82: 24-34.
115. Todaro M, Lombardo Y, Francipane MG, Alea MP, Cammareri P, Iovino F, Di Stefano AB, Di Bernardo C, Agrusa A, Condorelli G, Walczak H, Stassi G. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ 2008; 15:
116. Todaro M, Perez Alea M, Scopelliti A, Medema JP, Stassi G. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008; 7: 309-311.
117. Chiou SH, Kao CL, Chen YW, Chien CS, Hung SC, Lo JF, Chen YJ, Ku HH, Hsu MT, Wong TT. Identification of CD133- positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoSOne. 2008; 3: 1-13.
118. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-656.
119. Konopleva M, Zhao S, Hu W, Jiang S, Snell V, Weidner D, Jackson CE, Zhang X, Champlin R, Estey E, Reed JC, Andreeff M. The anti-apoptotic genes Bcl-X (L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 2002; 118: 521-534.
120. Abdullah LN, Chow EK. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2013; 2: 1-9.
121. Madjd Z, Mehrjerdi A, Sharif A, Molanei S, Shahzadi S, Asadi-Lari M. CD44+ cáncer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours, Cancer Immun 2009; 9:1-7.
122. D'Andrea FP. Intrinsic radiation resistance of mesenchymal cancer stem cells and implications for treatment response in a murine sarcoma model. Dan Med J 2012; 59: B4388.
123. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, Qian D, Lam JS, Ailles LE, Wong M, Joshua B, Kaplan MJ, Wapnir I, Dirbas FM, Somlo G, Garberoglio C, Paz B, Shen J, Lau SK, Quake SR, Brown JM, Weissman IL, Clarke MF. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009; 458:780-783.
124. Shi X, Zhang Y, Zheng J, Pan J. Reactive oxygen species in cancer stem cells. Antioxid Redox Signal 2012; 16:1215- 1228.
125. Acharya A, Das I, Chandhok D, Saha T. Redox regulation in cancer: a doubleedged sword with therapeutic potential. Oxid Med Cell Longev 2010; 3: 23-34.
126. Kobayashi CI, Suda T. Regulation of reactive oxygen species in stem cells and cancer stem cells. J Cell Physiol 2012; 227: 421-430.
127. Magni M, Shammah S, Schiró R, Mellado W, Dalla-Favera R, Gianni AM. Induction of cyclophosphamide-resistance by aldehyde- dehydrogenase gene transfer. Blood 1996; 87: 1097-1103.
128. Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L 1210 leukemia. Cancer Res 1984; 5: 5156-5160.
129. Friedman HS, Colvin OM, Kaufmann SH, Ludeman SM, Bullock N, Bigner DD, Griffith OW. Cyclophosphamide resistance in medulloblastoma. Cancer Res 1992; 52: 5373-5378.
130. Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L, Pickell K, Aguilar J, Lazetic S, Smith-Berdan S. Colorectal cáncer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 2008; 3:1-13.
131. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, Tripodo C, Russo A, Gulotta G, Medema JP, Stassi G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402.
132. Todaro M, Perez Alea M, Scopelliti A, Medema JP, Stassi G. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008; 7: 309-313.
133. Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008; 27:1749-1758.
134. Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP, Agrusa A, Dieli F, Zeuner A, Stassi G. Aurora- a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res. 2010; 70: 4655-4665.
135. Arvelo F, Cotte C. Hipoxia en la malignidad del cáncer. Invest Clín 2009; 50: 529-546.
136. Smith J, Tho LM, Xu N, Gillespie DA. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010; 108: 73-112.
137. Bao S, Wu Q, Mclendon R, Hao Y, Shi Q, Hjelmeland A, Dewhirst M, Bigner D, Rich J. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
138. Gallmeler E, Hermann P, Muelle M, Machado J, Ziesch A, De Toni E, Palagyi A, Eisen C, Ellwart J, Rivera J. Inhibition of ataxia telangiectasia and Rad 3 related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor initiating cell fraction. Stem Cells 2011; 29: 418-429.
139. Yates CC, Shepard CR, Stolz DB, Wells A. Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin. Br J Cancer 2007; 96: 1246-1252.
140. Vincan E, Brabletz T, Faux MC, Ramsay RG. A human three-dimensional cell line model allows the study of dynamic and reversible epithelial-mesenchymal and mesenchymal-epithelial transition that underpins colorectal carcinogenesis. Cells Tissues Organs 2007; 185: 20-28.
141. Chao YL, Shepard CR, Wells A. Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer 2010; 9: 1-18.
142. Brabletz T. To differentiate or not routes towards metástasis. Nat Rev Cancer 2012; 12: 425-436.
143. Tsuji T, Ibaragi S, Hu GF. Epithelialmesenchymal transition and cell cooperativity in metastasis. Cancer Res 2009; 69: 7135-7139.
144. Zhao Y, Bao Q, Renner A, Camaj P, Eichhorn M, Ischenko I, Angele M, Kleespies A, Jauch KW, Bruns C. Cancer stem cells and angiogenesis. Int J Dev Biol 2011; 55: 477-482.
145. Mimeault M, Batra SK. Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. J Cell Mol Med 2013; 17: 30-54.
146. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, Korkaya H, Heath A, Dutcher J, Kleer CG, Jung Y, Dontu G, Taichman R, Wicha MS. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011; 71: 614-624.